Testing immune response after prostate radiation with or without a drug
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study checks how your immune system’s cancer-fighting cells change after stereotactic body radiation (SBRT) to the prostate. It compares SBRT alone versus SBRT plus an immunotherapy drug (PDS01ADC) in men with intermediate- or high-risk localized prostate cancer treated with hormone therapy (ADT).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have localized intermediate- or high-risk prostate cancer (not spread beyond the pelvis).
- Your plan includes SBRT to the prostate and hormone therapy (ADT).
- You can provide prostate-tissue samples collected within 1 year before starting treatment (or you may need a biopsy).
- You’re at least 18 and can do the study visits (general health score must be < 2).
- Your blood tests and organ function meet safety limits (bone marrow, liver, kidneys, and blood-clotting tests).
- You must be able to have prostate biopsy/mri and understand/sign consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of radiation that adjusts to changes in your prostate during treatment. It aims to improve accuracy and reduce side effects for men with intermediate- or high-risk prostate cancer.
This study tests whether a special PET scan tracer (18F-DCFPyL) can show how well focused radiation (SBRT) is working for localized prostate cancer. It may help doctors spot treatment response earlier and tailor follow-up care.
This trial tests whether adding an experimental radioactive drug called PSMA-617 to standard radiation and hormone therapy helps men with high-risk prostate cancer that hasn't spread beyond the pelvis. The radioactive drug targets cancer cells specifically.
This trial tests whether giving a short course of hormone therapy (apalutamide) along with targeted, high-dose radiation (SBRT) is safe and effective for men with a specific type of intermediate-risk prostate cancer. You may benefit if you fit the exact risk and test criteria.
This trial tests whether adding hormone therapy (ADT) to stereotactic body radiation therapy (SBRT) works better than SBRT alone for men with a specific type of prostate cancer called 'unfavorable intermediate risk.' The goal is to see if the combination helps control the cancer better.
This trial tests a precise type of radiation (called SBRT) to the prostate bed for men whose PSA starts rising after prostate removal surgery. It aims to see if this targeted approach can effectively treat the recurrence without needing long-term hormone therapy.
Hear when a new Cancer Of Prostate trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.